An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.

MLA

Jacobs, Collin, et al. “An ISCOM Vaccine Combined with a TLR9 Agonist Breaks Immune Evasion Mediated by Regulatory T Cells in an Orthotopic Model of Pancreatic Carcinoma.” International Journal of Cancer, vol. 128, no. 4, Feb. 2011, pp. 897–907. EBSCOhost, https://doi.org/10.1002/ijc.25399.

APA

Jacobs, C., Duewell, P., Heckelsmiller, K., Wei, J., Bauernfeind, F., Ellermeier, J., Kisser, U., Bauer, C. A., Dauer, M., Eigler, A., Maraskovsky, E., Endres, S., & Schnurr, M. (2011). An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. International Journal of Cancer, 128(4), 897–907. https://doi.org/10.1002/ijc.25399

Chicago

Jacobs, Collin, Peter Duewell, Klaus Heckelsmiller, Jiwu Wei, Franz Bauernfeind, Jonathan Ellermeier, Ulrich Kisser, et al. 2011. “An ISCOM Vaccine Combined with a TLR9 Agonist Breaks Immune Evasion Mediated by Regulatory T Cells in an Orthotopic Model of Pancreatic Carcinoma.” International Journal of Cancer 128 (4): 897–907. doi:10.1002/ijc.25399.